Inhibition of lactate dehydrogenase activity as an approach to cancer therapy

Future Medicinal Chemistry

Volumn 6, Issue 4, 2014, Pages 429-445

  Fiume, Luigi ^a   Manerba, Marcella ^a   Vettraino, Marina ^a   Di Stefano, Giuseppina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON DIOXIDE; FLUORODEOXYGLUCOSE F 18; GALLOFLAVIN; GLUCOSE; GOSSYPOL; ISOENZYME; LACTATE DEHYDROGENASE; LACTIC ACID; OXAMIC ACID; PACLITAXEL; PYRIMIDINE DERIVATIVE; PYRUVIC ACID; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANAEROBIC METABOLISM; BIOLOGICAL FUNCTIONS; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CARCINOMA CELL; CATALYSIS; CELL METABOLISM; CELL PROLIFERATION; CITRIC ACID CYCLE; COLORECTAL CANCER; DISORDERS OF CARBOXYLIC ACID METABOLISM; DISSOCIATION CONSTANT; DRUG INDUSTRY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; GENETIC DISORDER; GLUCOSE METABOLISM; GLYCOLYSIS; HIGH THROUGHPUT SCREENING; HUMAN; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MITOCHONDRION; NONHUMAN; PEROXISOME; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

ENZYME INHIBITORS; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; NEOPLASMS; PROTEIN STRUCTURE, QUATERNARY; SMALL MOLECULE LIBRARIES;

EID: 84896995569     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.206     Document Type: Review

References (115)

1. Madern D. Molecular evolution within the l-malate and l-lactate dehydrogenase super-family. J. Mol. Evol. 54, 825-840 (2002).
2. Cristescu ME, Innes DJ, Stillman JH et al. d-and l-lactate dehydrogenases during invertebrate evolution. BMC Evol. Biol. 8, 268 (2008).
3. Banga I, Szent-Gyorgyi A, Vargha L. The coenzyme of lactic acid oxidation. Z. Physiol. Chem. 210, 228-235 (1932).
4. Straub FB. Crystalline lactic dehydrogenase from heart muscle. Biochem. J. 34, 483-486 (1940).
5. Vander Jagt DL, Hunsaker LA, Heidrich JE. Partial purification and characterization of lactate dehydrogenase from Plasmodium falciparum. Mol. Biochem. Parasitol. 4, 255-264 (1981).
6. Brown WM, Yowell CA, Hoard A et al. Comparative structural analysis and kinetic properties of lactate dehydrogenase from the four species of human malarial parasites. Biochemistry 43, 6219-6229 (2004).
7. Penna-Coutinho J, Cortopassi WA, Oliveira AA et al. Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies. PLoS ONE 6(7), e21237 (2011).
8. Choi SR, Pradhan A, Hammond NL et aetiDesign, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors. J. Med. Chem. 50(16), 3841-3850 (2007).
9. Choi SR, Beeler AB, Pradhan A et al. Generation of oxamic acid libraries: antimalarials and inhibitors of Plasmodium falciparum lactate dehydrogenase. J. Comb. Chem. 9(2), 292-300 (2007).
10. Markert CL, Shaklee JB, Whitt GS. Evolution of a gene. Multiple genes for LDH isozymes provide a model of the evolution of gene structure, function, and regulation. Science 189, 102-114 (1975).
11. Holmes RS, Goldberg E. Computational analyses of mammalian lactate dehydrogenases: human, mouse, opossum and platypus LDHs. Comput. Biol. Chem. 33, 379-385 (2009).
12. Yu Y, Deck JA, Hunsaker LA et al. Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4. Biochem. Pharmacol. 62, 81-89 (2001).
13. Read JA, Winter VJ, Eszes CM et al. Structural basis for altered activity of M-and H-isozyme forms of human lactate dehydrogenase. Proteins 43, 175-185 (2001).
14. Eszes CM, Sessions RB, Clarke AR et al. Removal of substrate inhibition in a lactate dehydrogenase from human muscle by a single residue change. FEBS Lett. 399, 193-197 (1996).
15. Hewitt CO, Eszes CM, Sessions RB et al. A general method for relieving substrate inhibition in lactate dehydrogenases. Protein Eng. 12, 491-496 (1999).
16. Everse J, Kaplan NO. Mechanisms of action and biological functions of various dehydrogenase isozymes. In: Isoenzymes II -Physiological function. Markert CL (Ed.). Academic Press, New York, USA, 29-43 (1975).
17. Deng H, Zheng J, Clarke A. Source of catalysis in the lactate dehydrogenase system. Ground-state interactions in the enzyme-substrate complex. Biochemistry 33, 2297-2305 (1994).
18. Swiderek K, Paneth P. Differences and similarities in binding of pyruvate and l-lactate in the active site of M4 and H4 isoforms of human lactate dehydrogenase. Arch. Biochem. Biophys. 505, 33-41 (2011).
19. Zielke HR, Sumbilla CM, Sevdalian DA et al. Lactate: a major product of glutamine metabolism by human diploid fibroblasts. J. Cell. Physiol. 104, 433-441 (1980).
20. Passarella S, de Bari L, Valenti D et al. Mitochondria and l-lactate metabolism. FEBS Lett. 582, 3569-3576 (2008).
21. Brooks GA. Cell-cell and intracellular lactate shuttles. J. Physiol. 587.23, 5591-5600 (2009).
22. Pérez-Ruiz T, Martínez-Lozano C, Tomás V. Flow injection determination of lactate based on a photochemical reaction using photometric and chemiluminescence detection. Analyst 124, 1517-1521 (1999).
23. Bauer CE, Elsen S, Bird TH. Mechanisms for redox control of gene expression. Annu. Rev. Microbiol. 53, 495-523 (1999).
24. Quistorff B, Grunnet N. The isoenzyme pattern of LDH does not play a physiological role; except perhaps during fast transitions in energy metabolism. Aging 3, 457-460 (2011).
25. Downer JD, Sevinsky JR, Ahn NG et al. Incorporating expression data in metabolic modelling: a case study of lactate dehydrogenase. J. Theor. Biol. 240, 464-474 (2006).
26. Baumgart E, Fahimi HD, Stich A et al. l-lactate dehydrogenase A4-and A3B isoforms are bone fide peroxisomal enzymes in rat liver. Evidence for involvement in intra-peroxisomal NADH oxidation. J. Biol. Chem. 271, 3846-3855 (1996).
27. McClelland GB, Khanna S, Gonzalez GF et al. Peroxisomal membrane monocarboxylate transporters: evidence for a redox shuttle system? Biochem. Biophys. Res. Commun. 304, 130-135 (2003).
28. Wanders RJA, Vreken P, Ferdinandusse S et al. Peroxisomal fatty acid a-and b-oxidation in humans: enzymology, peroxisomal metabolite transporters and peroxisomal diseases. Biochem. Soc. Trans. 29, 250-267 (2001).
29. Gertz EW, Wisneski JA, Stanley WC et al. Myocardial substrate utilization during exercise in humans. Dual carbon-labelled carbohydrate isotope experiments. J. Clin. Invest. 82, 2017-2025 (1988).
30. Pellerin L, Magistretti PM. Food for thought: challenging the dogmas. J. Cereb. Blood Flow Metab. 23, 1282-1286 (2003).
31. Brown AM, Baltan Tekkok S, Ransom BR. Energy transfer from astrocytes to axons: the role of CNS glycogen. Neurochem. Int. 45, 529-536 (2004).
32. Brooks GA, Dubouchaud H, Brown M et al. Role of mitochondrial lactate dehydrogenase and lactate oxidation in the intracellular lactate shuttle. Proc. Natl Acad. Sci. USA 96, 1129-1134 (1999).
33. Lemire J, Mailloux RJ, Appanna VD. Mitochondrial lactate dehydrogenase is involved in oxidative-energy metabolism in human astrocytoma cells (CCF-STTG1). PLoS ONE 3, e1550 (2008).
34. Patel GL, Thompson PE. Immunoreactive helix-destabilizing protein localized in transcriptionally active regions of Drosophila polytene chromosomes. Proc. Natl Acad. Sci. USA 77, 6749-6753 (1980).
35. Williams KR, Reddigari S, Patel GL. Identification of a nucleic acid helix-destabilizing protein from rat liver as lactate dehydrogenase-5. Proc. Natl Acad. Sci. USA 82, 5260-5264 (1985).
36. Calissano P, Volontè C, Biocca S et al. Synthesis and content of a DNA-binding protein with lactic dehydrogenase activity are reduced by nerve growth factor in the neoplastic cell line PC12. Exp. Cell Res. 161, 117-129 (1985).
37. Grosse F, Nasheuer HP, Scholtissek S et al. Lactate dehydrogenase and glyceraldehyde-phosphate dehydrogenase are single-stranded DNA-binding proteins that affect the DNA-polymerase-a-primase complex. Eur. J. Biochem. 160, 459-467 (1986).
38. Sharief FS, Wilson SH, Li SS. Identification of the mouse low-salt-eluting single-stranded DNA-binding protein as a mammalian lactate dehydrogenase-A isoenzyme. Biochem. J. 233, 913-916 (1986).
39. Kaiserman HB, Odenwald WF, Stowers DJ et al. A major single-stranded DNA binding protein from ovaries of the frog, Xenopus laevis, is lactate dehydrogenase. Biochim. Biophys. Acta 1008, 23-30 (1989).
40. Shamoo Y. Single-stranded DNA-binding proteins. In: Encyclopedia of Life Sciences. Macmillan Publishers Ltd, Nature Publishing Group, London, UK, 1-7 (2002).
41. Egyhazi E, Holst M, Pigon A et al. Effects of a DNA helix-destabilizing protein on transcription in living cells. Eur. J. Cell Biol. 48, 88-94 (1989).
42. Dai RP, Yu FX, Goh SR et al. Histone 2B (H2B) expression is confined to a proper NAD+/NADH redox status. J. Biol. Chem. 283, 26894-26901 (2008).
43. He H, Lee MC, Zheng LL et al. Integration of the metabolic/redox state, histone gene switching, DNA replication and S-phase progression by moonlighting metabolic enzymes. Biosci. Rep. 33, 187-197 (2013).
44. Wang XC, Jiang L, Zhou HM. Minimal functional unit of lactate dehydrogenase. J. Prot. Chem. 16, 227-231 (1997).
45. Levashov AV, Ugolnikova AV, Ivanov MV et al. Formation of homo-and heterooligomeric supramolecular structures by d-glyceraldehyde-3-phosphate dehydrogenase and lactate dehydrogenase in reversed micelles of aerosol OT in octane. Biochem. Mol. Biol. Int. 42, 527-534 (1997).
46. Cattaneo A, Biocca S, Corvaja N et al. Nuclear localization of a lactic dehydrogenase with single-stranded DNA-binding properties. Exp. Cell Res. 161, 130-140 (1985).
47. Warburg O. Uber den Stoffwechsel der Tumoren. Verlag Springer, Berlin (1926). Translated into English by Dickens F [The Metabolism of Tumours.] Constable, London, UK (1930).
48. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49, 24S-42S (2008).
49. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344 (2010).
50. DeBerardinis RJ, Lum JJ, Hatzivassiliou G et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20 (2008).
51. Buchakjian MR, Kornbluth S. The engine driving the ship: metabolic steering of cell proliferation and death. Nat. Rev. Mol. Cell Biol. 11, 715-727 (2010).
52. Vander Heiden MG, Locasale JW, Swanson KD et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329, 1492-1499 (2010).
53. Christofk HR, Vander Heiden MG, Wu N et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181-186 (2008).
54. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 15, 6479-6483 (2009).
55. Lu W, Hu Y, Chen G et al. Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol. 10, e1001326 (2012).
56. Bellance N, Lestienne P, Rossignol R. Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front Biosci. 14, 4015-4034 (2009).
57. Hunt TK, Aslam RS, Beckert S et al. Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid. Redox Signal. 9, 1115-1124 (2007).
58. Estrella V, Chen T, Lloyd M et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 73, 1524-1535 (2013).
59. Sonveaux P, Vegran F, Schroeder T et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-3942 (2008).
60. Pavlides S, Whitaker-Menezes D, Castello-Cros R et al. The reverse Warburg effect. Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8, 3984-4001 (2009).
61. Shim H, Chun YS, Lewis BC et al. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc. Natl Acad. Sci. USA 95, 1511-1516 (1998).
62. Yuneva M, Zamboni N, Oefner P et al. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol. 178, 93-105 (2007).
63. Pelicano H, Martin DS, Xu RH et al. Glycolysis inhibition for anticancer treatment. Oncogene 25, 4633-4646 (2006).
64. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267-277 (2010).
65. Fiume L. Inhibition of aerobic glycolysis in Yoshida ascites hepatoma by tartronic acid. Nature 187, 792-793 (1960).
66. Papacostantinou J, Colowick SP. The role of glycolysis in the growth of tumor cells. I. Effects of oxamic acid on the metabolism of Ehrlich tumor cells in vitro. J. Biol. Chem. 236, 278-284 (1961).
67. Manerba M, Vettraino M, Fiume L et al. Galloflavin (CAS 568-580-89): a novel inhibitor of lactate dehydrogenase. ChemMedChem 7, 311-317 (2012).
68. Granchi C, Bertini S, Macchia M et al. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr. Med. Chem. 17, 672-697 (2010).
69. Ward RA, Brassington C, Breeze AL et al. Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. J. Med. Chem. 55, 3285-3306 (2012).
70. Kohlmann A, Zech SG, Li F et al. Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors. J. Med. Chem. 56, 1023-1040 (2013).
71. Dragovich PS, Fauber BP, Corson LB et al. Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase. Bioorg. Med. Chem. Lett. 23, 3186-3194 (2013).
72. Miyajima H, Takahashi Y, Suzuki M et al. Molecular characterization of gene expression in human lactate dehydrogenase-A deficiency. Neurology 43, 1414-1419 (1993).
73. Maekawa M, Sudo K, Kanno T et al. Molecular characterization of genetic mutation in human lactate dehydrogenase-A (M) deficiency. Biochem. Biophys. Res. Commun. 168, 677-682 (1990).
74. Tsujno S, Shanske S, Keith A et al. Molecular genetic studies of muscle lactate dehydrogenase deficiency in white patients. Ann. Neurol. 36, 661-665 (1994).
75. Hidaka K, Ueda N, Hirata I et al. First case of missense mutation (LDH-H:R171P) in exon 4 of the lactate dehydrogenase gene detected in a Japanese patient. J. Hum. Genet. 44, 69-72 (1999).
76. Sudo K, Maekawa M, Ikawa S et al. A missense mutation found in human lactate dehydrogenase-B (H) variant gene. Biochem. Biophys. Res. Commun. 168, 672-676 (1990).
77. Maekawa M, Sudo K, Nagura K et al. Population screening of lactate dehydrogenase deficiency in Fukuoka Prefecture in Japan and molecular characterization of three independent mutations in the lactate dehydrogenase-B (H) gene. Hum. Gen. 93, 74-76 (1994).
78. Takatani T, Takaoka N, Tatsumi M et al. A novel missense mutation in human lactate dehydrogenase B-subunit gene. Mol. Gen. Metab. 73, 344-348 (2001).
79. Kanno T, Sudo K, Maekawa M et al. Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. Clin. Chim. Acta 173, 89-98 (1988).
80. Wakabayashi H, Tsuchiya M, Yoshino K et al. Hereditary deficiency of lactate dehydrogenase H-subunit. Intern. Med. 35, 550-554 (1996).
81. van Wijk R, van Solinge WW. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. Blood 106, 4034-4042 (2005).
82. Kanno T, Sudo K, Kitamura M et al. Lactate dehydrogenase A-subunit and B-subunit deficiencies: comparison of the physiological roles of LDH isozymes. In: Isozymes: Current Topics in Biological and Medical Research. Volume 7: Molecular Structure and Regulation. Alan R Liss Inc., NY, USA, 131-150 (1983).
83. Rong Y, Wu W, Kuang T et al. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 34, 1523-1530 (2013).
84. Yao F, Zhao T, Zhong C et al. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol. 34, 25-31 (2013).
85. Langhammer S, Najjar M, Hess-Stumpp H et al. LDH-A influences hypoxia-inducible factor 1a (HIF1 a) and is critical for growth of HT29 colon carcinoma cells in vivo. Target. Oncol. 6, 155-162 (2011).
86. Wang ZY, Loo TY, Shen JG et al. LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis. Breast Cancer Res. Treat. 131, 791-800 (2012).
87. Arseneault R, Chien A, Newington JT et al. Attenuation of LDHA expression in cancer cells leads to redox-dependent alterations in cytoskeletal structure and cell migration. Cancer Lett. 338, 255-266 (2013).
88. Zhang Y, Zhang X, Wang X et al. Inhibition of LDH-A by lentivirus-mediated small interfering RNA suppresses intestinal-type gastric cancer tumorigenicity through the downregulation of Oct4. Cancer Lett. 321, 45-54 (2012).
89. Zhou M, Zhao Y, Ding Y et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol. Cancer 9, 33 (2010).
90. Zhao Y, Liu H, Liu Z et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res. 71, 4585-4597 (2011).
91. Kim SH, Lee GM. Down-regulation of lactate dehydrogenase-A by siRNAs for reduced lactic acid formation of Chinese hamster overy cells producing thrombopoietin. Appl. Microbiol. Biotechnol. 74, 152-159 (2007).
92. Jeong DW, Cho IT, Kim TS et al. Effects of lactate dehydrogenase suppression and glycerol-3-phosphate dehydrogenase overexpression on cellular metabolism. Mol. Cell. Biochem. 284, 1-8 (2006).
93. Brown NJ, Higham SE, Perunovic B et al. Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PLoS ONE 8, e57697 (2013).
94. McCleland ML, Adler AS, Shang Y et al. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res. 72, 5812-5823 (2012).
95. Zha X, Wang F, Wang Y et al. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res. 71, 13-18 (2011).
96. McCleland ML, Adler AS, Deming L et al. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin. Cancer Res. 19, 773-784 (2012).
97. Kinoshita T, Nohata N, Yoshino H et al. Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. Int. J. Oncol. 40, 185-193 (2012).
98. Kim JH, Kim EL, Lee YK et al. Decreased lactate dehydrogenase B expression enhances claudin-1 mediated hepatoma cell invasiveness via mitochondrial defects. Exp. Cell Res. 317, 1108-1118 (2011).
99. Dodou K, Anderson RJ, Small DA et al. Investigations on gossypol: past and present developments. Expert Opin. Drugs 14, 1419-1434 (2005).
100. Papacostantinou J, Colowick SP. The role of glycolysis in the growth of tumor cells. II. The effect of oxamic acid on the growth of HeLa cells in tissue culture. J. Biol. Chem. 236, 285-288 (1961).
101. Aguirre-Alvarado C, Zaragoza-Martinez F, Rodriguez-Paez L et al. In vitro and in vivo trypanocydal activity of ethyl esters of N-allyl and N-propyl oxamates using different Trypanosoma cruzi strains. J. Enzyme Inhib. Med. Chem. 22, 227-233 (2007).
102. Lee CY, Moon YS, Yuan JH et al. Enzyme inactivation and inhibition by gossypol. Mol. Cell. Biochem. 47, 65-70 (1982).
103. Le A, Cooper CR, Gouw AM et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl Acad. Sci. USA 107, 2037-2042 (2010).
104. Sonpavde G, Matveev V, Burke JM et al. Randomized Phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann. Oncol. 23, 1803-1808 (2012).
105. Lin H, Gounder MK, Bertino JR et al. A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies. J. Pharm. Biomed. Anal. 66, 371-375 (2012).
106. Protein Data Bank. www.rcsb.org
107. Farabegoli F, Vettraino M, Manerba M et al. Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur. J. Pharm. Sci. 47, 729-738 (2012).
108. Vettraino M, Manerba M, Govoni M et al. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells via NAD/NADH-dependent inhibition of sirtuin-1. Anticancer Drugs 24, 862-870 (2013).
109. Fiume L, Vettraino M, Carnicelli D et al. Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells. Biochem. Biophys. Res. Commun. 430, 466-469 (2013).
110. Billiard J, Dellison JB, Brain J et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab. 1, 19 (2013).
111. Granchi C, Roy S, Giacomelli C et al. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J. Med. Chem. 54, 1599-1612 (2011).
112. Granchi C, Calvaresi EC, Tuccinardi T et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2- carboxylate (NHI) and malonic (Mal) scaffolds. Org. Biomol. Chem. 11, 6588-6596 (2013).
113. Rees DC, Congreve M, Murray CW et al. Fragment based lead discovery. Nat. Rev. Drug Discov. 3, 660-672 (2004).
114. Moorhouse AD, Spiteri C, Sharma P et al. Targeting glycolysis: a fragment based approach towards bifunctional inhibitors of hLDH-5. Chem. Commun. 47, 230-232 (2011).
115. Delmastro-Greenwood M, Piganelli JD. Changing the energy of an immune response. Am. J. Clin. Exp. Immunol. 2, 30-54 (2013).